Galectin-3: When to Order This Test

What Is Galectin-3 and Why Does It Matter?

Galectin-3 is a 30-kDa lectin protein secreted by activated macrophages in the heart, kidneys, and liver. Its primary clinical role centers on cardiac fibrosis: galectin-3 binds to extracellular matrix proteins, triggering fibroblast proliferation and collagen deposition that stiffens the myocardium over time. Measuring this protein in blood gives clinicians a window into active fibrotic remodeling that imaging alone may miss in early stages.

The protein first gained clinical attention after the PRIDE study (N=599) demonstrated that emergency department patients with acute dyspnea and galectin-3 levels above 17.8 ng/mL had a 14.3% 60-day mortality rate compared with 7.5% for those below the cutoff, even after adjusting for NT-proBNP and renal function (1). That finding made galectin-3 one of the first fibrosis-specific biomarkers validated in a prospective heart failure cohort.

Unlike BNP and NT-proBNP, which reflect acute myocardial wall stress (a hemodynamic snapshot), galectin-3 measures a slower, structural process. Think of BNP as a pressure gauge and galectin-3 as a corrosion sensor. Both readings matter, but they answer different clinical questions. A patient with a falling BNP but a rising galectin-3 may be hemodynamically compensated yet structurally deteriorating, a scenario that changes follow-up intensity and medication titration decisions.

The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure assigned galectin-3 a Class IIb recommendation (Level of Evidence B) for additive risk stratification in chronic heart failure (2). The guideline text specifically states: "Measurement of galectin-3 may be considered for additive risk stratification in patients with heart failure." This positions galectin-3 as a second-line prognostic marker rather than a diagnostic or screening test.

When to Order a Galectin-3 Test

The test serves three specific clinical scenarios. It is not a screening tool for asymptomatic patients without known cardiac disease.

Scenario 1: New heart failure diagnosis requiring risk stratification. After confirming HFrEF or HFpEF by echocardiography and natriuretic peptides, add galectin-3 to determine the patient's fibrotic burden. The COACH trial (N=592) found that patients with both elevated NT-proBNP and galectin-3 above 17.7 ng/mL had a 36.9% rate of all-cause mortality or HF rehospitalization at 18 months, versus 16.4% for those with neither biomarker elevated (3).

Scenario 2: Heart failure patients with recurrent hospitalizations despite optimized medical therapy. A persistently elevated or rising galectin-3 level between admissions signals ongoing fibrosis progression. The HF-ACTION trial substudy (N=895) showed that each 3 ng/mL increase in galectin-3 was independently associated with a 6% increase in all-cause mortality risk (HR 1.06 to 95% CI 1.01 to 1.12) (4). Rising galectin-3 despite guideline-directed therapy may prompt discussion of advanced therapies, referral to a heart failure specialist, or evaluation for mechanical circulatory support.

Scenario 3: Differentiating fibrotic from non-fibrotic cardiomyopathies. In patients with HFpEF and ambiguous cardiac MRI findings, a markedly elevated galectin-3 (above 25.9 ng/mL) supports a fibrotic etiology. This can influence decisions about aldosterone antagonist use, cardiac rehabilitation intensity, and follow-up imaging intervals.

Do not order galectin-3 in isolation. Pair it with NT-proBNP, renal function panel, and echocardiographic data for meaningful interpretation. A standalone result lacks clinical actionability.

Normal Galectin-3 Range and How to Interpret Results

Most commercial laboratories report a reference range below 17.8 ng/mL as normal. This threshold derives from the PRIDE study cohort and has been validated across multiple subsequent trials. Results break into three practical tiers.

Below 17.8 ng/mL. Low fibrotic risk. In a heart failure patient, this level predicts a 60-day mortality rate under 8% and correlates with better response to guideline-directed medical therapy. No galectin-3-specific action is needed. Continue standard management.

17.8 to 25.9 ng/mL. Intermediate fibrotic risk. Recheck in 3 to 6 months to assess trajectory. A rising trend carries more prognostic weight than a single value in this range. The DEAL-HF study (N=232) demonstrated that serial measurement improved reclassification of mortality risk beyond a single baseline value (5).

Above 25.9 ng/mL. High fibrotic risk. The PREVEND cohort (N=7,968 community-dwelling adults) showed that individuals in the top quintile of galectin-3 had a 2.1-fold higher risk of developing new-onset heart failure over 10 years compared to those in the lowest quintile, after adjustment for traditional cardiovascular risk factors (6). In patients with established heart failure, levels above 25.9 ng/mL predict markedly worse outcomes.

One critical caveat: galectin-3 is cleared by the kidneys. The PREVEND analysis confirmed that eGFR below 60 mL/min/1.73m² independently raises galectin-3 concentrations. Always interpret galectin-3 alongside creatinine and eGFR. A galectin-3 of 22 ng/mL in a patient with an eGFR of 35 may reflect renal retention rather than cardiac fibrosis.

Age modestly influences levels. Population studies show a mean increase of approximately 0.5 ng/mL per decade after age 50. Sex-based differences are small and not clinically significant in most assays.

What Does a High Galectin-3 Mean?

An elevated galectin-3 points to active fibrotic remodeling, but it does not tell you where the fibrosis is occurring without clinical context. The protein is expressed in multiple organ systems.

Cardiac fibrosis. This is the primary and most validated clinical application. High galectin-3 in a patient with known or suspected heart failure signals progressive myocardial stiffening, reduced ventricular compliance, and accelerated disease trajectory. Dr. Rudolf de Boer, who led several landmark galectin-3 studies at University Medical Center Groningen, has noted: "Galectin-3 appears to be not just a bystander but a direct mediator of cardiac fibrosis, making it both a prognostic marker and a potential therapeutic target."

Hepatic fibrosis. Galectin-3 rises in MASLD and MASH progression. A meta-analysis of 12 studies (N=2,413) found pooled sensitivity of 0.78 and specificity of 0.72 for galectin-3 in distinguishing significant hepatic fibrosis from mild or no fibrosis (7). If hepatic disease is suspected, correlate with FIB-4 score and transient elastography.

Renal fibrosis. Chronic kidney disease stages 3 to 5 independently raise galectin-3. The Framingham Heart Study offspring cohort (N=2,946) showed that higher galectin-3 predicted incident CKD (HR 1.47 per standard deviation increase) (8).

Malignancy. Certain cancers, particularly thyroid, colorectal, and breast, can produce galectin-3. An unexpectedly high result in a patient without obvious cardiac or hepatic disease warrants clinical evaluation for occult malignancy, especially when combined with unexplained weight loss or other systemic symptoms.

What Does a Low Galectin-3 Mean?

A galectin-3 below 11.0 ng/mL is reassuring. It indicates minimal active fibrotic signaling in the heart and other galectin-3-expressing tissues.

In heart failure populations, low galectin-3 predicts favorable outcomes. The CORONA trial (N=1,329 patients with systolic HF) found that patients in the lowest tertile of galectin-3 had the best survival at 3 years and derived the greatest absolute benefit from rosuvastatin therapy (9). Low galectin-3 may identify a subpopulation of heart failure patients with less structural remodeling and more reversible, hemodynamic pathology.

There is no clinical syndrome associated with pathologically low galectin-3. You do not need to "raise" galectin-3. A low value is consistently favorable across all studied populations. No guideline recommends intervention to increase galectin-3 levels.

How to Lower Galectin-3

No FDA-approved drug exists with a primary indication for galectin-3 reduction. Several interventions, however, have been shown to lower galectin-3 levels in clinical studies, and all of them carry independent cardiovascular benefits.

MRA therapy. Spironolactone 25 to 50 mg daily reduced galectin-3 levels by 15% to 20% at 6 months in a substudy of the Aldo-DHF trial (N=422 patients with HFpEF) (10). The mechanism may involve direct inhibition of aldosterone-mediated myocardial fibrosis. This is the most evidence-backed pharmacological approach to galectin-3 reduction.

SGLT2 inhibitors. Empagliflozin and dapagliflozin have demonstrated anti-fibrotic effects in preclinical models, and early clinical data from the EMPA-TROPISM trial (N=84) showed that empagliflozin reduced galectin-3 alongside improvements in myocardial strain and cardiac volumes at 6 months (11).

Modified citrus pectin (MCP). This is a galectin-3 inhibitor studied primarily in preclinical models and small human trials. A pilot study of 41 patients with hypertension and elevated galectin-3 showed that 9 g/day of MCP reduced galectin-3 by approximately 12% at 6 months. The data remain preliminary; MCP is not a guideline-recommended therapy (12).

Weight loss. Adipose tissue is a significant source of galectin-3. A post-hoc analysis of the Look AHEAD trial found that participants who lost 10% or more of body weight had significantly lower galectin-3 at 4-year follow-up compared with weight-stable controls (13).

Exercise. Regular aerobic exercise (150 minutes per week of moderate intensity) has been associated with lower galectin-3 in observational studies, likely through reduction of systemic inflammation and adiposity. The mechanism is indirect rather than through a specific molecular pathway.

Do not chase galectin-3 reduction as an isolated goal. Treat the underlying condition. Galectin-3 should track improvement alongside clinical status, echocardiographic parameters, and natriuretic peptides over months, not weeks.

Galectin-3 vs. Other Cardiac Biomarkers

Understanding where galectin-3 fits relative to BNP, NT-proBNP, and high-sensitivity troponin helps clinicians build a multi-marker strategy rather than relying on any single number.

BNP / NT-proBNP. These natriuretic peptides reflect myocardial wall stress from volume or pressure overload. They are first-line diagnostic and prognostic markers for heart failure. Levels change rapidly (hours to days) with hemodynamic shifts. Galectin-3, by contrast, moves slowly over weeks to months and reflects structural remodeling rather than acute hemodynamic load.

High-sensitivity troponin (hs-cTnI, hs-cTnT). These detect myocyte injury and necrosis. Chronic low-grade troponin elevation in heart failure indicates ongoing myocyte death. Galectin-3 adds a different dimension: it captures fibrosis and extracellular matrix turnover that troponin does not reflect.

sST2 (soluble suppression of tumorigenicity 2). This is the closest comparator to galectin-3. Both are fibrosis and inflammation markers with prognostic value in heart failure. The 2022 AHA/ACC/HFSA guidelines gave sST2 the same Class IIb recommendation as galectin-3 (2). Head-to-head comparisons are limited. Some data suggest sST2 may have superior prognostic discrimination in acute decompensated heart failure, while galectin-3 may better predict long-term fibrotic trajectory. Most centers do not order both simultaneously.

A reasonable multi-marker approach for a newly diagnosed heart failure patient includes NT-proBNP (hemodynamic status), hs-troponin (myocyte injury), and either galectin-3 or sST2 (fibrosis risk).

Ordering, Sample Handling, and Insurance Coverage

The galectin-3 blood test requires a standard venous blood draw. No fasting is needed. Serum and EDTA plasma are both acceptable sample types, though laboratories may specify a preference. The sample is stable at room temperature for up to 24 hours and at 2 to 8 degrees Celsius for up to 72 hours before processing.

The FDA-cleared BGM Galectin-3 assay (510(k) K101187) is the most widely available commercial test in the United States. Quest Diagnostics and several regional reference laboratories offer it. The CPT code is 82777.

Medicare covers the test under certain conditions, generally when ordered for a patient with an established heart failure diagnosis (ICD-10 I50.x). Private insurance coverage varies. Many plans require prior authorization or restrict coverage to cardiologists. Out-of-pocket cost ranges from $50 to $150, which is comparable to sST2 testing.

Order galectin-3 no more frequently than every 3 to 6 months for serial monitoring. More frequent testing has not been shown to improve clinical decision-making and adds cost without added prognostic resolution.

Clinical Pearls for Ordering Clinicians

Renal function is the single most important confounder. Always order a comprehensive metabolic panel alongside galectin-3. An eGFR below 60 mL/min/1.73m² raises galectin-3 by roughly 30% to 50% independent of cardiac fibrosis status.

Galectin-3 does not fluctuate acutely with diuretic dosing, fluid shifts, or short-term medication changes the way BNP does. If a patient's galectin-3 drops by more than 5 ng/mL between two measurements taken 3 months apart, that is a clinically meaningful improvement in fibrotic trajectory.

Do not use galectin-3 to diagnose heart failure. It lacks the sensitivity and specificity for diagnosis. The ACC/AHA guidelines are explicit: galectin-3 is for risk stratification in patients already carrying a heart failure diagnosis, not for confirming or ruling out the diagnosis itself.

Galectin-3 may add the most value in HFpEF, where traditional biomarkers like BNP are often only modestly elevated and the underlying pathology is disproportionately fibrotic and inflammatory. The TOPCAT trial biomarker substudy confirmed that galectin-3 independently predicted cardiovascular death in HFpEF patients even after adjustment for NT-proBNP (14).